PCSK9 and familial hypercholesterolemia: Mutations in the LDLR gene are present in 80–85% of cases in which a molecular genetic cause of familial hypercholesterolemia has been identified; APOB mutations are present in 5–7% of the patients; and PCSK9 mutations have been identified in fewer than 5% of the patients.